Prescribing stewardship is just one ethical consideration facing rheumatologists during the COVID-19 pandemic.
Search results for: hospital
FDA Approves Celecoxib in an Oral Solution
The FDA has approved a 25 mg/mL dose of an oral solution of celecoxib to treat adults with acute migraine…
Influential Lancet Article on HCQ Retracted
NEW YORK, June 4 (Reuters)—Three of the authors of an influential article that found hydroxychloroquine (HCQ) increased the risk of death in COVID-19 patients retracted the study, citing concerns about the quality of the data behind it. The anti-malarial drug has been controversial in part due to support from U.S. President Donald Trump, as well…
2 Pediatric Indications Sought for Golimumab
The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…
Longer Rituximab Therapy Boosts Remission in ANCA-Associated Vasculitis
NEW YORK (Reuters Health)—Long-term rituximab use lowers the chance of relapse of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), compared with standard maintenance therapy, according to a report from the MAINRITSAN3 randomized trial. “Physicians should consider AAV to be a long-lasting, chronic disease which requires maintenance therapy,” says Dr. Pierre Charles of Cochin Hospital, Paris…
In the Lungs: Asthma & COPD May Be Early, Independent Risk Factors for RA
Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…
Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
CHICAGO (Reuters)—Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on May 28. The preliminary results suggest doctors may want to refrain from…
U.S. Insurers Often Limit Biosimilar Coverage
(Reuters Health)—U.S. commercial health plans only covered biosimilar treatments as preferred products in 14% of coverage decisions last year, according to an analysis of publicly available data on coverage decisions.1 Researchers examined records from the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database, which has information on coverage decisions made by 17 of…
As Chinese Authorities Expand Use of Health Tracking Apps, Privacy Concerns Grow
SHANGHAI (Reuters)—China’s health tracking QR codes, which have played a key part in the country’s successful containment of COVID-19, now look set to play a much broader role in daily life as local authorities dream up new uses for the technology. Embedded in the popular WeChat and Alipay smartphone apps, the codes use self-reported and…
Few Medicare Advantage Plans Cover Social Needs for Chronically Ill Patients
(Reuters Health)—Most Medicare Advantage plans are not offering chronically ill enrollees supplemental benefits to address social needs, which were added to the government health program in 2018 in an effort to improve health outcomes and achieve cost savings, a U.S. study suggests.1 Researchers examined publicly available data on benefits and plan design for Medicare Advantage…
- « Previous Page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- …
- 330
- Next Page »